Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Recent years have seen a flood of studies linking genetic variations to particular diseases, and companies are trying to parlay those discoveries into direct-to-consumer genetic tests. ­Navigenics mails its subscribers containers for saliva samples. When it gets the samples back, it uses microarrays–chips studded with fragments of DNA–to screen the subscribers’ DNA for genetic variations linked to 18 diseases, including Alzheimer’s and colon cancer. Such genetic screening has received little clinical evaluation, however, so whether it helps prevent disease is unclear.


Credit: Joshua Scott

Product: Health Compass

Cost: $2,500 for the initial test; $250 a year for continued consultation

Source: www.navigenics.com

Company: Navigenics

0 comments about this story. Start the discussion »

Tagged: Biomedicine, DNA, genetic testing, gene-sequencing technology

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me